Clone:
REA108
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Alternative names:
CCR7, BLR-2, CC-CKR-7, CCR-7, Cdw197, CMKBR7, EBI-1

Specifications for CD197 antibodies

Overview

REA108 recognizes human CD197 which is a chemokine receptor with a C-C motif that mediates homing of T cells to secondary lymphoid organs via high endothelial venules (HEV) and is also known as CCR7. For example, naive T cells migrate very efficiently through lymph nodes using the adhesion molecules L-selectin, CD62L, and CCR7. Ligands for CCR7, e.g. CCL19, are expressed by the HEV of secondary lymphoid organs, by parenchymal cells within T cell zones of lymph nodes, and by endothelial cells at the openings of lymphatic vessels within peripheral tissues. Expression of CCR7 and the CD45RA isoform distinguishes three subsets of T cells: naive T cells (CCR7
+
CD45RA
+
), central memory T cells (CCR7
+
CD45RA
), and effector memory T cells (CCR7
CD45RA
).
Additional information: Clone REA108 displays negligible binding to Fc receptors.

Alternative names

CCR7, BLR-2, CC-CKR-7, CCR-7, Cdw197, CMKBR7, EBI-1

Detailed product information

Technical specifications

CloneREA108
Isotyperecombinant human IgG1
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD197
Alternative names of antigenCCR7, BLR-2, CC-CKR-7, CCR-7, Cdw197, CMKBR7, EBI-1
Molecular mass of antigen [kDa]40
Distribution of antigenB cells, dendritic cells, NK cells, macrophages, thymocytes

Resources for CD197 antibodies

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD197 antibodies

Publications

  1. Bacher, P. et al. (2014)
    Identification of immunogenic antigens from
    Aspergillus fumigatus
    by direct multi parameter characterization of specific conventional and regulatory CD4
    +
    T cells.
    J. Immunol. 193: 3332-3343
  2. Sallusto, F. et al. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712
  3. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  4. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  6. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition

Seems like you are coming from USA!
Do you want to visit our website in your country?